Basal cell carcinoma
☆ A cikin sakamakon Stiftung Warentest na 2022 daga Jamus, gamsuwar mabukaci tare da ModelDerm ya ɗan yi ƙasa kaɗan fiye da biyan shawarwarin telemedicine.
Cututtukan da ke shafar fatar hanci a cikin tsofaffi ana yawan gano su kamar Basal cell carcinoma. Hanci wuri ne na yau da kullun na faruwa ga irin wannan nau'in kansar fata.
Basal cell carcinoma na iya kasancewa tare da iyakoki marasa daidaituwa da ulcers.
Basal cell carcinoma ana iya yin kuskure da wart.
References
Basal cell carcinoma (BCC) shine mafi yawan nau'in ciwon daji na fata. Hasken rana shine babban dalilin. Kusan dukkan lamuran BCC suna nuna siginar bushiya a cikin binciken kwayoyin halitta. Ana samun jiyya daban-daban kuma an zaɓa bisa ga haɗarin sake dawowa, mahimmancin adana nama, fifikon haƙuri, da girman cuta.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinomas sune nau'in ciwon daji na fata da aka fi sani da manya masu fata masu shekaru 50 zuwa sama. Adadin su na karuwa a duniya, musamman saboda fallasa hasken rana. Wasu yanayi na kwayoyin halitta na iya sa mutane suyi saurin kamuwa da waɗannan cututtukan daji tun suna ƙanana. Basal cell carcinomas ya bambanta da tsanani, kama daga raunin da za a iya magance shi cikin sauƙi ko na nodular zuwa mafi girman waɗanda ke buƙatar tattaunawa a cikin ƙungiyoyin likitoci na musamman. Hasashen ya dogara da yuwuwar dawowar ciwon daji ko ikonsa na lalata nama da ke kusa. Tiyata shine daidaitaccen magani ga mafi yawan lokuta, yana tabbatar da cirewa daidai da ƙananan damar sake dawowa. Ƙananan hanyoyi masu cin zarafi na iya magance raunuka na sama.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Babban magani na BCC shine tiyata. Don babban haɗari ko maimaita BCC, musamman a wurare masu mahimmanci, ana ba da shawarar tiyata mai sarrafa micrographically. Marasa lafiya masu ƙarancin haɗari na zahiri na BCC na iya yin la'akari da jiyya na zahiri ko hanyoyin lalata. Photodynamic far yana aiki da kyau don na sama da ƙananan haɗari nodular BCCs. Don ci gaba na cikin gida ko BCC mai tsauri, ana ba da shawarar masu hana bushiya (vismodegib, sonidegib) . Idan akwai ci gaban cuta ko rashin haƙuri ga masu hana Hedgehog, ana iya ɗaukar immunotherapy tare da anti-PD1 antibody (cemiplimab) . Radiotherapy wani zaɓi ne mai kyau ga marasa lafiya waɗanda ba za su iya yin tiyata ba, musamman ma tsofaffi marasa lafiya. Ana iya la'akari da Electrochemotherapy idan tiyata ko radiotherapy ba zaɓi bane.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
Abubuwan haɗari sun haɗa da haskakawa ga hasken ultraviolet, farfadowa na radiation, tsawon lokaci mai tsawo ga arsenic da rashin aikin tsarin rigakafi (misali dasa gabobin jiki). Fitar da hasken UV yayin ƙuruciya yana da illa musamman.
Bayan ganewar asali ta biopsy, magani yawanci ta hanyar cirewa ne. Wannan na iya zama ta hanyar cirewa mai sauƙi idan ciwon daji yana da ƙananan; Idan ciwon daji ba karami ba ne, ana ba da shawarar tiyata na Mohs gabaɗaya.
Basal cell carcinoma yana da aƙalla kashi 32% na duk cututtukan daji a duniya. Na ciwon daji na fata ban da melanoma, kusan kashi 80% na ciwon daji na basal-cell. A Amurka, kusan kashi 35% na fararen fata maza da kashi 25% na mata farare suna fama da ciwon sankara na basal cell a wani lokaci a rayuwarsu.
○ Diagnosis da Magani
#Dermoscopy
#Skin biopsy
#Mohs surgery